Blood Biomarker of Alzheimer's Disease (AD)

Currently, no cures or disease modifying therapies exist for Alzheimer's disease (AD). This is partially due to the inability to detect the disease before it has progressed to a stage where there are clinical manifestations. The identification and validation of high throughput biomarkers to measure disease progression (as well as identify pre-clinical disease onset) is critical to the development of disease-modifying or even preventative therapies. In this study, we are testing a blood biomarker for stratification of Alzheimer's disease patients and healthy volunteers. This study may lead to future blood tests that may help earlier diagnosis of Alzheimer's disease and detect the disease progression.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Alzheimer Disease Brain Diseases Central Nervous System Diseases Dementia Mental Disorders Nervous System Diseases Neurocognitive Disorders Neurodegenerative Diseases Tauopathies

Age range

50 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Duke University

Durham, North Carolina, 27710, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Alzheimer's Disease Patients:

50 years and older
AD patient who is seen at the Memory Disorders Clinic
AD diagnosis
Non smoking
No cancer treatment in the last 5 years
Informed consent from the patient or the patient's legally authorized representative (LAR)
Patient and/or LAR able to read and speak English

Healthy Control Participants:

50 years and older
Non smoking
No cancer treatment in the last 5 years
Age matched to AD subject
Able to read and speak English

Exclusion criteria

Alzheimer's Disease Patients:

Known additional neurological disease

Healthy Control Participants:

Neurological degenerative diseases (such as Parkinson's, Alzheimer's or Huntington's)

Treatment and study plan

Primary outcomes

Biological marker of Alzheimer's disease

Time frame: Day 1

Test for blood biological marker of Alzheimer's disease, mtDNA damage

Sponsors and collaborators

Lead sponsor

Duke University

Other

Registry information

Official study title

mtDNA Damage in Alzheimer's Disease (AD)

Important dates

Study start: 2018
Primary completion: 2019
Study completion: 2019
First posted: Nov 13, 2017
Registry last updated: Oct 23, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed